Education
About Us
Working with TipRanks
Follow Us
SeaStar Medical Holding (ICU)
NASDAQ:ICU
ICU Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.31 - $4.46
Previous CloseN/A
Volume52.61K
Average Volume (3M)2.40M
Market Cap
$16.81M
Enterprise Value-$1.48M
Total Cash (Recent Filing)$6.30M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Nov 12, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding27,914,597
10 Day Avg. Volume4,893,890
30 Day Avg. Volume2,397,859
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.09
Enterprise Value/Revenue-1.93
Enterprise Value/Gross Profit-2.00
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$2.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAn independent DSMB recommended continuation of the NEUTRALIZE-AKI trial with no safety concerns, noting a potential efficacy signal.
Financial StabilityThe company raised net proceeds of approximately $7.6M in two registered direct offerings, which could extend cash runway.
Market OpportunityThe analyst maintains a Buy rating and a $2.00 price target, supported by the novel technology and significant market opportunity in adult AKI.
Bears Say
Capital RequirementsICU will likely require significant capital to fund the trial, pursue regulatory approval, and support parallel development efforts across the SCD platform.
SeaStar Medical Holding News
ICU FAQ
What was SeaStar Medical Holding’s price range in the past 12 months?
SeaStar Medical Holding lowest stock price was $0.30 and its highest was $4.46 in the past 12 months.
What is SeaStar Medical Holding’s market cap?
SeaStar Medical Holding’s market cap is $16.81M.
When is SeaStar Medical Holding’s upcoming earnings report date?
SeaStar Medical Holding’s upcoming earnings report date is Nov 12, 2025 which is in 43 days.
How were SeaStar Medical Holding’s earnings last quarter?
SeaStar Medical Holding released its earnings results on Aug 13, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.25.
Is SeaStar Medical Holding overvalued?
According to Wall Street analysts SeaStar Medical Holding’s price is currently Undervalued.
Does SeaStar Medical Holding pay dividends?
SeaStar Medical Holding does not currently pay dividends.
What is SeaStar Medical Holding’s EPS estimate?
SeaStar Medical Holding’s EPS estimate is -0.15.
How many shares outstanding does SeaStar Medical Holding have?
SeaStar Medical Holding has 27,914,597 shares outstanding.
What happened to SeaStar Medical Holding’s price movement after its last earnings report?
SeaStar Medical Holding reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went up 20.548%.
Which hedge fund is a major shareholder of SeaStar Medical Holding?
Currently, no hedge funds are holding shares in ICU
SeaStar Medical Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (233.33% Upside)
$2.00 (233.33% Upside)
Insider Transactions
Bought Shares
Worth $38.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.4%
Last 30 Days ▲ 16.2%
Last 30 Days ▲ 16.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.17%
12-Months-Change
Fundamentals
Return on Equity
1475.93%
Trailing 12-Months
Asset Growth
141.79%
Trailing 12-Months
Company Description
SeaStar Medical Holding
SeaStar Medical Holding (ICU) is a medical technology company focused on developing and commercializing innovative therapies for acute and chronic conditions, particularly those affecting the kidneys and immune system. The company's core product is the Selective Cytopheretic Device (SCD), a patented therapeutic device designed to treat acute kidney injury (AKI) and other inflammatory conditions by selectively targeting and modulating activated leukocytes in the bloodstream.
ICU Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects significant progress in revenue and FDA approvals, alongside challenges in trial enrollment and operational delays. The company remains optimistic about future opportunities in both pediatric and adult markets.View all ICU earnings summariesICU Stock 12 Month Forecast
Average Price Target
$2.00
▲(233.33% Upside)
Technical Analysis
Plus Therapeutics
―
Eterna Therapeutics
―
GeoVax Labs
―
Addex Therapeutics
―
Sensei Biotherapeutics
―
Ownership Overview
1.77% Insiders
0.44% Mutual Funds
0.36% Other Institutional Investors
97.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---